Palbociclib vs Ribociclib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: CDK4 and CDK6 · full HR+/HER2- Metastatic Breast Cancer pipeline

Palbociclib · Ibrance

Marketed by Pfizer

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Reliable signal

NCT01740427 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled phase 3 trial with 666 participants. Its primary clinical endpoint, investigator-assessed progression-free survival using RECIST criteria, was significantly improved with palbociclib plus letrozole (hazard ratio 0.576; p<0.000001), supporting a strong evidence grade.

Next expected readout: November 2026 · NCT02605486 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6) (met)

Result source: NCT02297438

Ribociclib

Marketed by Novartis

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Reliable signal

NCT02422615 · Phase 3 · completed

The study randomly assigned 726 participants to ribociclib plus fulvestrant or placebo plus fulvestrant and was quadruple-blinded for the primary comparison. Its radiographically assessed progression-free survival endpoint was significantly better with ribociclib; participants were later unblinded and offered crossover after a protocol amendment.

Next expected readout: November 2026 · NCT02608216 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3) (met)

Result source: NCT02422615

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointPalbociclibRibociclib
PFS, median24.8 vs 14.5+10.3 vs placebon 444NCT01740427
20 other results
20.5 vs 12.8+7.7 vs placebon 484NCT02422615
9 other results
OS, median53.9 vs 51.2+2.7 vs placebon 444NCT01740427
14 other results
63.9 vs 51.4+12.5 vs placebon 334NCT01958021
1 other result
ORR46.4% vs 38.3%+8.1 vs placebon 444NCT01740427
15 other results
32.4% vs 21.5%+10.9 vs placebon 484NCT02422615
6 other results
  • 40.9% vs 29.7% n 335 · Phase 3 · secondary NCT02278120
  • 40.7% vs 27.5% n 334 · Phase 3 · secondary NCT01958021
  • 29.3% n 3246 · Phase 3 · secondary NCT02941926
  • 45.3% 600 mg · n 188 · Phase 2 · primary NCT03822468
  • 41.5% 400 mg · n 188 · Phase 2 · primary NCT03822468
  • 66.1% vs 61.8% 600 mg · n 112 · Phase 2 · secondary NCT03839823
Clinical benefit rate85.8% vs 71.2%+14.6 vs placebon 444NCT01740427
10 other results
70.2% vs 62.8%+7.4 vs placebon 484NCT02422615
4 other results
  • 79.1% vs 69.7% n 335 · Phase 3 · secondary NCT02278120
  • 79.6% vs 72.8% n 334 · Phase 3 · secondary NCT01958021
  • 70.7% n 3246 · Phase 3 · secondary NCT02941926
  • 81.3% vs 74.5% 600 mg · n 112 · Phase 2 · secondary NCT03839823

PFS, median

Palbociclib
24.8 vs 14.5+10.3 vs placebon 444NCT01740427
20 other results
Ribociclib
20.5 vs 12.8+7.7 vs placebon 484NCT02422615
9 other results

OS, median

Palbociclib
53.9 vs 51.2+2.7 vs placebon 444NCT01740427
14 other results
Ribociclib
63.9 vs 51.4+12.5 vs placebon 334NCT01958021
1 other result

ORR

Palbociclib
46.4% vs 38.3%+8.1 vs placebon 444NCT01740427
15 other results
Ribociclib
32.4% vs 21.5%+10.9 vs placebon 484NCT02422615
6 other results
  • 40.9% vs 29.7% n 335 · Phase 3 · secondary NCT02278120
  • 40.7% vs 27.5% n 334 · Phase 3 · secondary NCT01958021
  • 29.3% n 3246 · Phase 3 · secondary NCT02941926
  • 45.3% 600 mg · n 188 · Phase 2 · primary NCT03822468
  • 41.5% 400 mg · n 188 · Phase 2 · primary NCT03822468
  • 66.1% vs 61.8% 600 mg · n 112 · Phase 2 · secondary NCT03839823

Clinical benefit rate

Palbociclib
85.8% vs 71.2%+14.6 vs placebon 444NCT01740427
10 other results
Ribociclib
70.2% vs 62.8%+7.4 vs placebon 484NCT02422615
4 other results
  • 79.1% vs 69.7% n 335 · Phase 3 · secondary NCT02278120
  • 79.6% vs 72.8% n 334 · Phase 3 · secondary NCT01958021
  • 70.7% n 3246 · Phase 3 · secondary NCT02941926
  • 81.3% vs 74.5% 600 mg · n 112 · Phase 2 · secondary NCT03839823
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
12 other shared endpoints and safety

Coverage. Palbociclib: 16 of 16 rows · Ribociclib: 16 of 16 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPalbociclib
Rows use multiple source trials
Ribociclib
Rows use multiple source trials
Clinical Benefit
event count · % of participants
76.2% (n=206) vs 82.4% (n=187) Capecitabine*a,b,c
NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 157 Participants as posted
43.3% (n=60) vs 25.4% (n=59) placebo @ 24wk*a,b,c
NCT02632045 · Phase 2 · registry result, not featured evidence · combination · converted to % from 26 Participants as posted
Clinical Benefit
responder rate · % of participants
No placebo or comparator arm
64% (n=47)d,b,e,c
NCT02668666 · Phase 2 · registry result, not featured evidence
1 other source trial
83.3% (n=12)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
70.7% (n=3246)d,b,e,c
NCT02941926 · Phase 3 · combination
Clinical Benefit
event count · % of participants
No placebo or comparator arm
83.3% (n=54)*b,e,c
NCT03007979 · Phase 2 · registry result, not featured evidence · combination · converted to % from 45 Participants as posted
4 other source trials
40% (n=5) @ 26wk*
NCT02913430 · Phase 1 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
60% (n=5)*
NCT02913430 · Phase 1 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
50% (n=2) @ 26wk*
NCT02913430 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
100% (n=2)*
NCT02913430 · Phase 1 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
70.7% (n=188)*600 mgf,b,e,c
NCT03822468 · Phase 2 · registry result, not featured evidence · converted to % from 133 Participants as posted
show 1 more dose
75.5% (n=188)*400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence · converted to % from 142 Participants as posted
Duration of Response
time to event · months
20.1 vs 16.7 placebo monthsg,c
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
7 other source trials
10.4 vs 9 Fulvestrant months
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
22.4 vs 19.4 placebo months
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
30.3 vs 24.9 placebo months
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
9.7 vs 11.2 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
20.9 vs 11.1 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
20.2 vs 11.1 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
20.3 vs 11.1 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
NA vs NA placebo monthsg,c
NCT02422615 · Phase 3 · combination
3 other source trials
21.3 vs 17.5 placebo months
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
45.2 vs 17.6 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
37 vs 17.6 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
Duration of Response
time to event · months
No placebo or comparator arm
5.55 months*125mgf,b,e,c
NCT02630693 · Phase 2 · registry result, not featured evidence · converted to months from 169 days as posted
show 1 more dose
4.14 months*100mg
NCT02630693 · Phase 2 · registry result, not featured evidence · converted to months from 126 days as posted
28.8 months600 mgf,b,e,c
NCT03822468 · Phase 2 · registry result, not featured evidence
show 1 more dose
26.5 months400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
FACT-B
absolute change · score
No placebo or comparator arm
End of Treatment
-9.17 score125 mg + 2.5 mgd,h,c
End of Treatment
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
-4.1 scored,h,c
End of Treatment
NCT02941926 · Phase 3 · combination
ORR
event count · % of participants
22.8% (n=206) vs 29.4% (n=187) Capecitabine*a,b,c
NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 47 Participants as posted
20% (n=35) vs 11.4% (n=35) placebo*a,b,c
NCT02632045 · Phase 2 · registry result, not featured evidence · combination · converted to % from 7 participants as posted
ORR
responder rate · % of participants
No placebo or comparator arm
30% (n=47)d,b,e,c
NCT02668666 · Phase 2 · registry result, not featured evidence
3 other source trials
47.6% (n=42)125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
33.3% (n=12)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
19.2% (n=26)
NCT02499146 · Phase 1 · registry result, not featured evidence · combination
29.3% (n=3246)d,b,e,c
NCT02941926 · Phase 3 · combination
2 other source trials
41.5% (n=188)400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
45.3% (n=188)600 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
ORR
event count · % of participants
No placebo or comparator arm
33.3% (n=54)*b,c
NCT03007979 · Phase 2 · registry result, not featured evidence · combination · converted to % from 18 Participants as posted
8 other source trials
0% (n=3) @ 24wk*100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted
0% (n=3) @ 24wk*150 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted
6.7% (n=15) @ 24wk*150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 1 Participants as posted
10% (n=10) @ 24wk*300 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 1 Participants as posted
0% (n=16) @ 24wk*50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted
0% (n=6) @ 24wk*75 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted
0% (n=3) @ 24wk*75 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted
4% (n=75) @ 24wk*50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 3 Participants as posted
50% (n=2)*b,c
NCT03477396 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
Overall Survival
time to event · months
No placebo or comparator arm
35.61 months*d,b,c
NCT03633331 · Phase 2 · registry result, not featured evidence · combination · converted to months from 1084 days as posted
8 other source trials
20.73 months100mg
NCT02630693 · Phase 2 · registry result, not featured evidence
21.39 months125mg
NCT02630693 · Phase 2 · registry result, not featured evidence
NA months
NCT03530696 · Phase 2 · registry result, not featured evidence
35.1 months
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
37.9 months
NCT03691493 · Phase 2 · registry result, not featured evidence · combination
NA months125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
18.7541 months
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
NA monthsf,d,b,c
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
show 2 more doses
NA months
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
NA months
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
Overall Survival
responder rate · % of participants
No placebo or comparator arm
90% (n=10) @ 48wk300 mg QDf,i,b,j
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
show 7 more doses
100% (n=3) @ 48wk150 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
100% (n=15) @ 48wk150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
100% (n=3) @ 48wk100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
83.3% (n=6) @ 48wk75 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
100% (n=3) @ 48wk75 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
100% (n=16) @ 48wk50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
84.2% (n=75) @ 48wk50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
93.3% (n=307) @ 48wkf,i,b,j
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
show 2 more doses
87.5% (n=26) @ 48wk
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
86.1% (n=154) @ 48wk
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
PFS
time to event · months
No placebo or comparator arm
29.4 months*d,b,c
NCT03633331 · Phase 2 · registry result, not featured evidence · combination · converted to months from 895 days as posted
11 other source trials
9.33 months100mg
NCT02630693 · Phase 2 · registry result, not featured evidence
11.3 months125mg
NCT02630693 · Phase 2 · registry result, not featured evidence
9.13 months
NCT02668666 · Phase 2 · registry result, not featured evidence
8.3 months
NCT03530696 · Phase 2 · registry result, not featured evidence
16.9 months
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
30.4 months
NCT03691493 · Phase 2 · registry result, not featured evidence · combination
6.53 months100mg
NCT02384239 · Phase 2 · registry result, not featured evidence
9.4 months125mg
NCT02384239 · Phase 2 · registry result, not featured evidence
18.6 months
NCT02499146 · Phase 1 · registry result, not featured evidence · combination
4.131147 months
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
NA months
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
21.8 monthsf,d,b,c
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
show 2 more doses
16.5 months
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
8.8 months
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
Dropout rate
n/a: no completion milestonek
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 55 more results
n/a: no completion milestone
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
n/a: no completion milestone
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
69.1%Palbociclib+Letrozole Australia Co
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
34%Palbociclib+Letrozole India Cohort
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort 1: Palbociclib Plus Exemest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort 2: Palbociclib Plus Fulvest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
0%
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
1.1%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
87.5%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
1.1%125mg
NCT02630693 · Phase 2 · registry result, not featured evidence
0%100mg
NCT02630693 · Phase 2 · registry result, not featured evidence
0%
NCT02668666 · Phase 2 · registry result, not featured evidence
1.4%
NCT03644186 · Phase 2 · registry result, not featured evidence · combination
1.8%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
1.6%
NCT02536742 · Phase 2 · registry result, not featured evidence
12.5%Single Agent T-DM1
NCT03530696 · Phase 2 · registry result, not featured evidence
2.6%T-DM1 With Palbociclib
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
2.8%
NCT03691493 · Phase 2 · registry result, not featured evidence · combination
0%125mg
NCT02384239 · Phase 2 · registry result, not featured evidence
0%100mg
NCT02384239 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone125 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
—125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
—125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
—Ph2P1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
—Ph2P2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
100%Phase 1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
97.6%Phase 2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone300 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone150 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone75 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone75 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone50 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone25 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone25 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—125mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
—100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
—100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT02499146 · Phase 1 · registry result, not featured evidence · combination
0%Fulvestrant + Palbociclib
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
0%Tamoxifen + Palbociclib
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
—8 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone8 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
—6 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone6 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
—5 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone5 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestoneRibociclib + Fulvestrantl
NCT02422615 · Phase 3 · combination
show 27 more results
—Ribociclib + Fulvestrant (On-treat
NCT02422615 · Phase 3 · combination
n/a: no completion milestoneRibociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Ribociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Crossover to Ribociclib + Letrozol
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
n/a: no completion milestoneRibociclib + Letrozole
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
59.9%
NCT02941926 · Phase 3 · combination
68.7%Ribociclib + Letrozole Cohort A
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
—Ribociclib + Letrozole Cohort B
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
76.9%Ribociclib + Letrozole Cohort B1
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
87.9%Ribociclib + Letrozole Cohort B2
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestonePK Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—PK Cohort - Ribociclib (On-treatme
NCT03671330 · Phase 2 · registry result, not featured evidence
—PK Cohort - Ribociclib (Post-treat
NCT03671330 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonePostmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonePremenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone600 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—600mg
NCT03822468 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—400mg
NCT03822468 · Phase 2 · registry result, not featured evidence
0%
NCT03477396 · Phase 2 · registry result, not featured evidence · combination
68.8%600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
3.2%
NCT02632045 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
7.2%k
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 55 more results
8.9%
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
3.9%Palbociclib+Letrozole Australia Co
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
2%Palbociclib+Letrozole India Cohort
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
5.2%Cohort 1: Palbociclib Plus Exemest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
2%Cohort 2: Palbociclib Plus Fulvest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
2.3%
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
—
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
—
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
—
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
—125mg
NCT02630693 · Phase 2 · registry result, not featured evidence
—100mg
NCT02630693 · Phase 2 · registry result, not featured evidence
—
NCT02668666 · Phase 2 · registry result, not featured evidence
—
NCT03644186 · Phase 2 · registry result, not featured evidence · combination
—
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
—
NCT02536742 · Phase 2 · registry result, not featured evidence
—Single Agent T-DM1
NCT03530696 · Phase 2 · registry result, not featured evidence
—T-DM1 With Palbociclib
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
—
NCT03691493 · Phase 2 · registry result, not featured evidence · combination
—125mg
NCT02384239 · Phase 2 · registry result, not featured evidence
—100mg
NCT02384239 · Phase 2 · registry result, not featured evidence
0%125 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
—125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
—125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
16.7%100 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
—Ph2P1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
—Ph2P2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
0%Phase 1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
15.5%Phase 2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
—300 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—150 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—75 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—75 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—50 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—25 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—25 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—125mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
—100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
—100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
11.5%
NCT02499146 · Phase 1 · registry result, not featured evidence · combination
—Fulvestrant + Palbociclib
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
—Tamoxifen + Palbociclib
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
—8 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
50%8 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
—6 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
33.3%6 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
—5 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
0%5 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
10.5%Ribociclib + Fulvestrantl
NCT02422615 · Phase 3 · combination
show 27 more results
—Ribociclib + Fulvestrant (On-treat
NCT02422615 · Phase 3 · combination
4.8%Ribociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Ribociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Crossover to Ribociclib + Letrozol
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
11.4%Ribociclib + Letrozole
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
15.5%
NCT02941926 · Phase 3 · combination
22.6%Ribociclib + Letrozole Cohort A
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
—Ribociclib + Letrozole Cohort B
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
23.1%Ribociclib + Letrozole Cohort B1
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
17.8%Ribociclib + Letrozole Cohort B2
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
11.8%PK Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—PK Cohort - Ribociclib (On-treatme
NCT03671330 · Phase 2 · registry result, not featured evidence
—PK Cohort - Ribociclib (Post-treat
NCT03671330 · Phase 2 · registry result, not featured evidence
6.5%Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
1.3%Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
12.8%600 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—600mg
NCT03822468 · Phase 2 · registry result, not featured evidence
11.2%400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—400mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—
NCT03477396 · Phase 2 · registry result, not featured evidence · combination
7.1%600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
—
NCT02632045 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
28.2%k
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 55 more results
22.6%
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
20.2%
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
29.6%Palbociclib+Letrozole Australia Co
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
18%Palbociclib+Letrozole India Cohort
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
22.7%Cohort 1: Palbociclib Plus Exemest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
14.1%Cohort 2: Palbociclib Plus Fulvest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
24.6%
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
—
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
38%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
15.7%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
13.5%125mg
NCT02630693 · Phase 2 · registry result, not featured evidence
10%100mg
NCT02630693 · Phase 2 · registry result, not featured evidence
32.7%
NCT02668666 · Phase 2 · registry result, not featured evidence
54.2%
NCT03644186 · Phase 2 · registry result, not featured evidence · combination
27.8%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
73%
NCT02536742 · Phase 2 · registry result, not featured evidence
21.4%Single Agent T-DM1
NCT03530696 · Phase 2 · registry result, not featured evidence
21.1%T-DM1 With Palbociclib
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
—
NCT03691493 · Phase 2 · registry result, not featured evidence · combination
5.9%125mg
NCT02384239 · Phase 2 · registry result, not featured evidence
13.9%100mg
NCT02384239 · Phase 2 · registry result, not featured evidence
0%125 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
9.5%125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
33.3%125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
0%100 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
30.3%Ph2P1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
24%Ph2P2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
16.7%Phase 1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
26.5%Phase 2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
20%300 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
33.3%150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
0%150 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
13.3%150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
16.7%100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
33.3%100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
16.7%75 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
0%75 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
0%50 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
11.1%50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
0%50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
12%50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
20%25 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
40%25 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
100%125mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
83.3%100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
87.5%100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
15.4%
NCT02499146 · Phase 1 · registry result, not featured evidence · combination
40%Fulvestrant + Palbociclib
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
0%Tamoxifen + Palbociclib
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
25%8 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
—8 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
16.7%6 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
—6 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
33.3%5 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
—5 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
—Ribociclib + Fulvestrantl
NCT02422615 · Phase 3 · combination
show 27 more results
37.1%Ribociclib + Fulvestrant (On-treat
NCT02422615 · Phase 3 · combination
—Ribociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
24.2%Ribociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
25%Crossover to Ribociclib + Letrozol
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
32.3%Ribociclib + Letrozole
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—
NCT02941926 · Phase 3 · combination
30.4%Ribociclib + Letrozole Cohort A
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
27.3%Ribociclib + Letrozole Cohort B
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
19.2%Ribociclib + Letrozole Cohort B1
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
28.7%Ribociclib + Letrozole Cohort B2
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
—PK Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
29.4%PK Cohort - Ribociclib (On-treatme
NCT03671330 · Phase 2 · registry result, not featured evidence
0%PK Cohort - Ribociclib (Post-treat
NCT03671330 · Phase 2 · registry result, not featured evidence
—Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
27.3%Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
0%Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
17.7%Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
0%Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
19.7%600mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
20.2%400mg
NCT03822468 · Phase 2 · registry result, not featured evidence
0%
NCT03477396 · Phase 2 · registry result, not featured evidence · combination
—600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
15.2%600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
6.7%
NCT02632045 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
k
neutropenia 69.4% (placebo 3.6%)
arthralgia 42.1% (placebo 40.1%)
fatigue 41.2% (placebo 29.3%)
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 49 more results
neutropenia 67%
fatigue 43.8%
nausea 36.5%
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
neutrophil count decreased 66.7% (placebo 11.1%)
white blood cell count decreased 64.3% (placebo 9.9%)
neutropenia 44.6% (placebo 7%)
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
neutropenia 72.4%
fatigue 65.1%
nausea 37.5%
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
neutropenia 57%
anaemia 22%
alopecia 17%
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
neutrophil count decreased 62.7%
fatigue 55.3%
hypertension 34%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 63.1%
fatigue 51%
hypertension 36.9%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
neutropenia 70%
leukopenia 34.6%
anaemia 33.8%
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 92.4%
white blood cell decreased 87%
fatigue 84.8%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 92.2%
nausea 52.9%
stomatitis 41.2%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
125mg
fatigue 82%
nausea 53.9%
back pain 46.1%
NCT02630693 · Phase 2 · registry result, not featured evidence
100mg
fatigue 85.6%
nausea 52.2%
insomnia 48.9%
NCT02630693 · Phase 2 · registry result, not featured evidence
neutrophil count decreased 71.4%
fatigue 65.3%
white blood cell decreased 65.3%
NCT02668666 · Phase 2 · registry result, not featured evidence
diarrhea 65.3%
anemia 48.6%
platelet count decreased 38.9%
NCT03644186 · Phase 2 · registry result, not featured evidence · combination
white blood cell count decreased 96.3%
neutrophil count decreased 87%
anemia 79.6%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
nausea 57.1%
aspartate aminotransferase increased 50%
fatigue 50%
NCT03530696 · Phase 2 · registry result, not featured evidence
neutrophil count decreased 84.2%
platelet count decreased 76.3%
white blood cell count decreased 76.3%
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
125mg
neutrophil count decreased 26.5%
hypertension 0%
NCT02384239 · Phase 2 · registry result, not featured evidence
100mg
neutrophil count decreased 13.9%
hypertension 5.6%
NCT02384239 · Phase 2 · registry result, not featured evidence
125 mg
white blood cell count decreased 83.3%
diarrhoea 66.7%
neutrophil count decreased 66.7%
NCT01684215 · Phase 2 · registry result, not featured evidence
125 mg + 2.5 mg
neutrophil count decreased 81%
stomatitis 76.2%
white blood cell count decreased 71.4%
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
125 mg + 2.5 mg
neutrophil count decreased 100%
white blood cell count decreased 100%
diarrhoea 66.7%
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
100 mg
neutrophil count decreased 83.3%
white blood cell count decreased 66.7%
aspartate aminotransferase increased 33.3%
NCT01684215 · Phase 2 · registry result, not featured evidence
neutropenia 78.8%
leukopenia 48.5%
fatigue 42.4%
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
neutropenia 72%
fatigue 40%
leukopenia 40%
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
neutropenia 91.7%
fatigue 83.3%
leukopenia 66.7%
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
neutropenia 74.7%
leukopenia 43.4%
fatigue 41%
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
300 mg QD
nausea 40%
fatigue 30%
headache 30%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
150 mg QD
neutrophil count decreased 100%
anaemia 66.7%
fatigue 66.7%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
150 mg BID
abdominal pain 66.7%
ggt increased 66.7%
nausea 66.7%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
150 mg QD
nausea 40%
headache 26.7%
hypertension 26.7%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
100 mg QD
white blood cell count decreased 91.7%
neutrophil count decreased 58.3%
anaemia 41.7%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
100 mg QD
abdominal pain upper 33.3%
arthralgia 33.3%
back pain 33.3%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
75 mg BID
arthralgia 33.3%
fall 33.3%
fatigue 33.3%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
75 mg QD
hypophosphataemia 66.7%
blood alkaline phosphatase increased 33.3%
breast pain 33.3%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
50 mg BID
alt increased 50%
anaemia 50%
cough 50%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
50 mg QD
neutrophil count decreased 77.8%
white blood cell count decreased 77.8%
anaemia 66.7%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
50 mg QD
fatigue 25%
ggt increased 18.8%
arthralgia 12.5%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
50 mg QD
ggt increased 14.7%
covid-19 10.7%
ast increased 9.3%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
25 mg BID
nausea 60%
neutrophil count decreased 60%
white blood cell count decreased 60%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
25 mg QD
neutrophil count decreased 80%
white blood cell count decreased 70%
anaemia 50%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
125mg
mucositis oral 100%
neutrophil count decreased 100%
platelet count decreased 100%
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
100mg
mucositis oral 100%
neutrophil count decreased 83.3%
fatigue 50%
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
100mg
mucositis oral 96.9%
neutrophil count decreased 87.5%
fatigue 65.6%
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
neutrophil count decreased 61.5%
platelet count decreased 57.7%
white blood cell count decreased 57.7%
NCT02499146 · Phase 1 · registry result, not featured evidence · combination
dyspnea 60%
neutrophil count decreased 60%
skin and subcutaneous tissue disorders - other 60%
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
blood and lymphatic system disorders - other 50%
hypertension 50%
neutrophil count decreased 50%
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
8 mg
diarrhea 75%
oral mucositis 75%
dry skin 50%
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
6 mg
fatigue 83.3%
oral mucositis 83.3%
dry mouth 66.7%
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
5 mg
anemia 100%
constipation 100%
dry skin 100%
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
l
neutropenia 57.8% (placebo 2.5%)
nausea 46.8% (placebo 31.1%)
diarrhoea 34% (placebo 22.4%)
NCT02422615 · Phase 3 · combination
show 18 more results
neutropenia 57.9% (placebo 6.5%)
arthralgia 38.8% (placebo 36.2%)
neutrophil count decreased 35.5% (placebo 1.5%)
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
nausea 75% (placebo 32.1%)
anaemia 50% (placebo 7.3%)
diarrhoea 50% (placebo 26.7%)
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
neutropenia 65.3% (placebo 5.5%)
nausea 54.8% (placebo 32.1%)
fatigue 43.4% (placebo 36.1%)
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
neutropenia 50.8%
nausea 40.8%
fatigue 38.6%
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
neutropenia 48.1%
nausea 42.1%
fatigue 40.4%
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
fatigue 57.7%
neutropenia 57.7%
hot flush 42.3%
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
neutropenia 46.5%
nausea 43.3%
fatigue 37.6%
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 100% (placebo 23.4%)
white blood cell count decreased 100% (placebo 33.8%)
anaemia 94.1% (placebo 13%)
NCT03671330 · Phase 2 · registry result, not featured evidence
aspartate aminotransferase increased 12.5% (placebo 40.3%)
blood alkaline phosphatase increased 6.3% (placebo 27.3%)
blood cholesterol increased 6.3% (placebo 16.9%)
NCT03671330 · Phase 2 · registry result, not featured evidence
neutrophil count decreased 85.7% (placebo 23.4%)
white blood cell count decreased 80.5% (placebo 33.8%)
anaemia 48.1% (placebo 13%)
NCT03671330 · Phase 2 · registry result, not featured evidence
alanine aminotransferase increased 1.4% (placebo 40.3%)
aspartate aminotransferase increased 1.4% (placebo 40.3%)
blood bilirubin increased 1.4% (placebo 13%)
NCT03671330 · Phase 2 · registry result, not featured evidence
neutrophil count decreased 88.6% (placebo 23.4%)
white blood cell count decreased 87.3% (placebo 33.8%)
anaemia 55.7% (placebo 13%)
NCT03671330 · Phase 2 · registry result, not featured evidence
neutrophil count decreased 2.7% (placebo 23.4%)
alanine aminotransferase increased 1.4% (placebo 40.3%)
aspartate aminotransferase increased 1.4% (placebo 40.3%)
NCT03671330 · Phase 2 · registry result, not featured evidence
600mg
neutropenia 66.5%
leukopenia 27.7%
anaemia 26.1%
NCT03822468 · Phase 2 · registry result, not featured evidence
400mg
neutropenia 53.2%
alanine aminotransferase increased 26.1%
aspartate aminotransferase increased 21.8%
NCT03822468 · Phase 2 · registry result, not featured evidence
alanine aminotransferase increased 100%
alkaline phosphatase increased 100%
aspartate aminotransferase increased 100%
NCT03477396 · Phase 2 · registry result, not featured evidence · combination
600 mg
neutropenia 65.2%
anaemia 35.7%
leukopenia 25.9%
NCT03839823 · Phase 2 · registry result, not featured evidence
neutropenia 71.7% (placebo 15.3%)
fatigue 33.3% (placebo 32.2%)
aspartate aminotransferase increased 25% (placebo 28.8%)
NCT02632045 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aTrial phases differ: Phase 2 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cThe assessment timepoint is not available for both results.
  4. dTrial phases differ: Phase 3 versus Phase 2.
  5. eTreatment context has not been resolved for both arms.
  6. fThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  7. gPopulation context differs: eligible sex differs (ALL versus FEMALE).
  8. hPopulation context differs: registered conditions differ.
  9. iTrial phases differ: Phase 3 versus Phase 1/2.
  10. jTreatment context differs: combination versus monotherapy.
  11. kPopulation comparability has not been reviewed for 53 of these studies.
  12. lPopulation comparability has not been reviewed for 24 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Palbociclib

Complete 1% (n=100)
responder rate · % of participants
No placebo or comparator arm
Percentage of participants with complete response
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
1.3% (n=152)
Percentage of participants with complete response
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
Partial 28% (n=100)
responder rate · % of participants
No placebo or comparator arm
Percentage of participants with partial response
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
11.8% (n=152)
Percentage of participants with partial response
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
ORR 29% (n=100)
absolute value · percentage points
No placebo or comparator arm
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
show 3 more results
13.2% (n=152)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
24.8% (n=129)
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
55% (n=47)
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
EQ-5D Utility 0.698 score
absolute value · score
No placebo or comparator arm
End of Treatment (EOT)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
EQ-5D Utility -0.147 score
absolute change · score
No placebo or comparator arm
End of Treatment (EOT)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
EQ-5D-VAS 73.6 score
absolute value · score
No placebo or comparator arm
End of Treatment (EOT)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
EQ-5D VAS -3.2 score
absolute change · score
No placebo or comparator arm
End of Treatment (EOT)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
EORTC QLQ-C30 Global Health Status 3.28 vs 1.97 Capecitabine score
absolute change · score
Global health status / QoL
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Physical Functioning -1.73 vs -2.94 Capecitabine score
absolute change · score
Physical functioning
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Role Functioning -1.09 vs -4.97 Capecitabine score
absolute change · score
Role functioning
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Emotional Functioning 6.78 vs 8.67 Capecitabine score
absolute change · score
Emotional functioning
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Cognitive Functioning -2.18 vs -2.42 Capecitabine score
absolute change · score
Cognitive functioning
NCT02028507 · Phase 3 · registry result, not featured evidence · combination

+ 61 further endpoints in the CSV export.

Ribociclib

Time to Response 4.9 vs 3.2 Combination Chemotherapy months600 mg
time to event · months
NCT03839823 · Phase 2 · registry result, not featured evidence
show 4 more results
NA vs NA placebo months
NCT02422615 · Phase 3 · combination
NA vs NA placebo months
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
3.7 vs 5.5 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
3.6 vs 5.5 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
Time to Progression 27.1 months
time to event · months
No placebo or comparator arm
NCT02941926 · Phase 3 · combination
FACT-B 0.2 score @ 4wk
absolute change · score
No placebo or comparator arm
Cycle 2 Day 1
NCT02941926 · Phase 3 · combination
FACT-B 0.1 score @ 8wk
absolute change · score
No placebo or comparator arm
Cycle 3 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -0.3 score @ 12wk
absolute change · score
No placebo or comparator arm
Cycle 4 Day 1
NCT02941926 · Phase 3 · combination
FACT-B 0 score @ 16wk
absolute change · score
No placebo or comparator arm
Cycle 5 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -0.8 score @ 20wk
absolute change · score
No placebo or comparator arm
Cycle 6 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -0.9 score @ 28wk
absolute change · score
No placebo or comparator arm
Cycle 8 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -1.2 score @ 36wk
absolute change · score
No placebo or comparator arm
Cycle 10 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -1.6 score @ 44wk
absolute change · score
No placebo or comparator arm
Cycle 12 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -2 score @ 56wk
absolute change · score
No placebo or comparator arm
Cycle 15 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -2 score @ 68wk
absolute change · score
No placebo or comparator arm
Cycle 18 Day 1
NCT02941926 · Phase 3 · combination

+ 34 further endpoints in the CSV export.

Breast Cancer

Shared mechanism: CDK4 and CDK6 · full Breast Cancer pipeline

Palbociclib · Ibrance

Marketed by Pfizer

Approved in Breast Cancersmall molecule
Reliable signal

NCT01740427 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled phase 3 trial with 666 participants. Its primary clinical endpoint, investigator-assessed progression-free survival using RECIST criteria, was significantly improved with palbociclib plus letrozole (hazard ratio 0.576; p<0.000001), supporting a strong evidence grade.

Next expected readout: November 2026 · NCT02605486 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6) (met)

Result source: NCT02297438

Ribociclib

Marketed by Novartis

Approved in Breast Cancersmall molecule
Reliable signal

NCT02422615 · Phase 3 · completed

The study randomly assigned 726 participants to ribociclib plus fulvestrant or placebo plus fulvestrant and was quadruple-blinded for the primary comparison. Its radiographically assessed progression-free survival endpoint was significantly better with ribociclib; participants were later unblinded and offered crossover after a protocol amendment.

Next expected readout: November 2026 · NCT02608216 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3) (met)

Result source: NCT02422615

Results for Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Palbociclib: 21 of 21 rows · Ribociclib: 21 of 21 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPalbociclib
Rows use multiple source trials
Ribociclib
Rows use multiple source trials
Clinical Benefit
responder rate · % of participants
85.8% (n=444) vs 71.2% (n=222) placeboa,b
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
8 other source trials
66.3% (n=347) vs 39.7% (n=174) Fulvestrant
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
79.3% (n=169) vs 80.1% (n=171) placebo
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
77.9% (n=145) vs 79.6% (n=142) placebo
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
76.9% (n=169) vs 73.1% (n=171) placebo
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
78.1% (n=128) vs 71.8% (n=131) placebo
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
76.5% (n=34) vs 58% (n=81) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
84% (n=50) vs 58% (n=81) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
81% (n=84) vs 58% (n=81) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
70.2% (n=484) vs 62.8% (n=242) placeboa,b
NCT02422615 · Phase 3 · combination
3 other source trials
79.1% (n=335) vs 69.7% (n=337) placebo
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
79.6% (n=334) vs 72.8% (n=334) placebo
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
81.3% (n=112) vs 74.5% (n=110) Combination Chemotherapy600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
Clinical Benefit
event count · % of participants
76.2% (n=206) vs 82.4% (n=187) Capecitabine*c,d,b
NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 157 Participants as posted
43.3% (n=60) vs 25.4% (n=59) placebo @ 24wk*c,d,b
NCT02632045 · Phase 2 · registry result, not featured evidence · combination · converted to % from 26 Participants as posted
Clinical Benefit
responder rate · % of participants
No placebo or comparator arm
64% (n=47)e,d,f,b
NCT02668666 · Phase 2 · registry result, not featured evidence
1 other source trial
83.3% (n=12)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
70.7% (n=3246)e,d,f,b
NCT02941926 · Phase 3 · combination
Clinical Benefit
event count · % of participants
No placebo or comparator arm
83.3% (n=54)*d,f,b
NCT03007979 · Phase 2 · registry result, not featured evidence · combination · converted to % from 45 Participants as posted
10 other source trials
0.67% (n=36) @ 24wk100mg
NCT02384239 · Phase 2 · registry result, not featured evidence
0.75% (n=32) @ 24wk125mg
NCT02384239 · Phase 2 · registry result, not featured evidence
33.3% (n=3) @ 24wk*100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 1 Participants as posted
33.3% (n=3) @ 24wk*150 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 1 Participants as posted
26.7% (n=15) @ 24wk*150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 4 Participants as posted
50% (n=10) @ 24wk*300 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 5 Participants as posted
43.8% (n=16) @ 24wk*50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 7 Participants as posted
16.7% (n=6) @ 24wk*75 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 1 Participants as posted
0% (n=3) @ 24wk*75 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted
50.7% (n=75) @ 24wk*50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 38 Participants as posted
70.7% (n=188)*600 mgg,d,f,b
NCT03822468 · Phase 2 · registry result, not featured evidence · converted to % from 133 Participants as posted
show 1 more dose
75.5% (n=188)*400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence · converted to % from 142 Participants as posted
Duration of Response
time to event · months
20.1 vs 16.7 placebo monthsa,b
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
7 other source trials
10.4 vs 9 Fulvestrant months
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
22.4 vs 19.4 placebo months
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
30.3 vs 24.9 placebo months
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
9.7 vs 11.2 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
20.9 vs 11.1 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
20.2 vs 11.1 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
20.3 vs 11.1 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
NA vs NA placebo monthsa,b
NCT02422615 · Phase 3 · combination
3 other source trials
21.3 vs 17.5 placebo months
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
45.2 vs 17.6 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
37 vs 17.6 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
Duration of Response
time to event · months
No placebo or comparator arm
5.55 months*125mgg,d,f,b
NCT02630693 · Phase 2 · registry result, not featured evidence · converted to months from 169 days as posted
show 1 more dose
4.14 months*100mg
NCT02630693 · Phase 2 · registry result, not featured evidence · converted to months from 126 days as posted
28.8 months600 mgg,d,f,b
NCT03822468 · Phase 2 · registry result, not featured evidence
show 1 more dose
26.5 months400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
FACT-B
absolute change · score
No placebo or comparator arm
End of Treatment
-9.17 score125 mg + 2.5 mge,h,b
End of Treatment
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
-4.1 scoree,h,b
End of Treatment
NCT02941926 · Phase 3 · combination
ORR
responder rate · % of participants
46.4% (n=444) vs 38.3% (n=222) placeboa,b
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
12 other source trials
21% (n=347) vs 8.6% (n=174) Fulvestrant
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
37.3% (n=169) vs 31.6% (n=171) placebo
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
43.4% (n=145) vs 38% (n=142) placebo
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
40.2% (n=169) vs 33.9% (n=171) placebo
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
52.3% (n=128) vs 43.5% (n=131) placebo
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
50% (n=112) vs 49.1% (n=108) Anastrozole + Palbociclib @ 12wk
NCT04436744 · Phase 2 · registry result, not featured evidence · combination
44.1% (n=34) vs 33.3% (n=81) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
55.6% (n=27) vs 39.4% (n=66) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
42% (n=50) vs 33.3% (n=81) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
55.3% (n=21) vs 39.4% (n=66) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
42.9% (n=84) vs 33.3% (n=81) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
55.4% (n=65) vs 39.4% (n=66) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
32.4% (n=484) vs 21.5% (n=242) placeboa,b
NCT02422615 · Phase 3 · combination
3 other source trials
40.9% (n=335) vs 29.7% (n=337) placebo
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
40.7% (n=334) vs 27.5% (n=334) placebo
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
66.1% (n=112) vs 61.8% (n=110) Combination Chemotherapy600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
ORR
event count · % of participants
22.8% (n=206) vs 29.4% (n=187) Capecitabine*c,d,b
NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 47 Participants as posted
20% (n=35) vs 11.4% (n=35) placebo*c,d,b
NCT02632045 · Phase 2 · registry result, not featured evidence · combination · converted to % from 7 participants as posted
ORR
responder rate · % of participants
No placebo or comparator arm
30% (n=47)e,d,f,b
NCT02668666 · Phase 2 · registry result, not featured evidence
2 other source trials
47.6% (n=42)125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
33.3% (n=12)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
29.3% (n=3246)e,d,f,b
NCT02941926 · Phase 3 · combination
3 other source trials
41.5% (n=188)400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
45.3% (n=188)600 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
16.7% (n=12)
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
ORR
event count · % of participants
No placebo or comparator arm
33.3% (n=54)*d,b
NCT03007979 · Phase 2 · registry result, not featured evidence · combination · converted to % from 18 Participants as posted
8 other source trials
0% (n=3) @ 24wk*100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted
0% (n=3) @ 24wk*150 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted
6.7% (n=15) @ 24wk*150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 1 Participants as posted
10% (n=10) @ 24wk*300 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 1 Participants as posted
0% (n=16) @ 24wk*50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted
0% (n=6) @ 24wk*75 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted
0% (n=3) @ 24wk*75 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 0 Participants as posted
4% (n=75) @ 24wk*50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy · converted to % from 3 Participants as posted
50% (n=2)*d,b
NCT03477396 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
Overall Survival
time to event · months
53.9 vs 51.2 placebo monthsg,a,b
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more dose
53.8 vs 49.8 placebo months
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
NA vs 40 placebo monthsa,b
NCT02422615 · Phase 3 · combination
5 other source trials
NA vs 40.9 placebo months
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
63.9 vs 51.4 placebo months
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
NA vs 55.5 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
69.2 vs 55.5 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
NA vs NA Combination Chemotherapy months600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
Overall Survival
time to event · months
No placebo or comparator arm
35.61 months*e,d,b
NCT03633331 · Phase 2 · registry result, not featured evidence · combination · converted to months from 1084 days as posted
6 other source trials
20.73 months100mg
NCT02630693 · Phase 2 · registry result, not featured evidence
21.39 months125mg
NCT02630693 · Phase 2 · registry result, not featured evidence
NA months
NCT03530696 · Phase 2 · registry result, not featured evidence
35.1 months
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
37.9 months
NCT03691493 · Phase 2 · registry result, not featured evidence · combination
NA months125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
NA monthsg,e,d,b
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
show 2 more doses
NA months
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
NA months
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
Overall Survival
responder rate · % of participants
No placebo or comparator arm
90% (n=10) @ 48wk300 mg QDg,i,d,j
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
show 7 more doses
100% (n=3) @ 48wk150 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
100% (n=15) @ 48wk150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
100% (n=3) @ 48wk100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
83.3% (n=6) @ 48wk75 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
100% (n=3) @ 48wk75 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
100% (n=16) @ 48wk50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
84.2% (n=75) @ 48wk50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
93.3% (n=307) @ 48wkg,i,d,j
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
show 2 more doses
87.5% (n=26) @ 48wk
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
86.1% (n=154) @ 48wk
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
PFS
time to event · months
24.8 vs 14.5 placebo monthsa,b
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
9 other source trials
9.2 vs 3.8 Fulvestrant months
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
21.5 vs 13.9 placebo months
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
21.6 vs 16.4 placebo months
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
7.3 vs 9.4 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
7.5 vs 9.4 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
8 vs 10.6 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
26.1 vs 10.2 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
18.1 vs 10.2 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
20.2 vs 10.2 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
20.5 vs 12.8 placebo monthsg,a,b
NCT02422615 · Phase 3 · combination
show 1 more dose
NA vs 10.9 placebo months
NCT02422615 · Phase 3 · combination
PFS
time to event · months
No placebo or comparator arm
29.4 months*e,d,b
NCT03633331 · Phase 2 · registry result, not featured evidence · combination · converted to months from 895 days as posted
8 other source trials
9.33 months100mg
NCT02630693 · Phase 2 · registry result, not featured evidence
11.3 months125mg
NCT02630693 · Phase 2 · registry result, not featured evidence
9.13 months
NCT02668666 · Phase 2 · registry result, not featured evidence
8.3 months
NCT03530696 · Phase 2 · registry result, not featured evidence
16.9 months
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
30.4 months
NCT03691493 · Phase 2 · registry result, not featured evidence · combination
6.53 months100mg
NCT02384239 · Phase 2 · registry result, not featured evidence
9.4 months125mg
NCT02384239 · Phase 2 · registry result, not featured evidence
21.8 monthsg,e,d,b
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
show 2 more doses
16.5 months
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
8.8 months
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
Progressive Disease
event count · % of participants
No placebo or comparator arm
Progressive Disease
36.4% (n=11)*g,k,h,b
NCT03530696 · Phase 2 · registry result, not featured evidence · converted to % from 4 Participants as posted
show 1 more dose
14.3% (n=35)*
NCT03530696 · Phase 2 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted
75% (n=12) @ 12wk*k,h,b
Progressive disease
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 9 Participants as posted
Dropout rate
n/a: no completion milestonel
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 48 more results
n/a: no completion milestone
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
n/a: no completion milestone
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
69.1%Palbociclib+Letrozole Australia Co
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
34%Palbociclib+Letrozole India Cohort
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort 1: Palbociclib Plus Exemest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort 2: Palbociclib Plus Fulvest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
19.5%
NCT01864746 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
0%
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
1.1%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
87.5%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
1.1%125mg
NCT02630693 · Phase 2 · registry result, not featured evidence
0%100mg
NCT02630693 · Phase 2 · registry result, not featured evidence
0%
NCT02668666 · Phase 2 · registry result, not featured evidence
1.4%
NCT03644186 · Phase 2 · registry result, not featured evidence · combination
1.8%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
1.6%
NCT02536742 · Phase 2 · registry result, not featured evidence
12.5%Single Agent T-DM1
NCT03530696 · Phase 2 · registry result, not featured evidence
2.6%T-DM1 With Palbociclib
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
2.8%
NCT03691493 · Phase 2 · registry result, not featured evidence · combination
3.6%
NCT04436744 · Phase 2 · registry result, not featured evidence · combination
0%125mg
NCT02384239 · Phase 2 · registry result, not featured evidence
0%100mg
NCT02384239 · Phase 2 · registry result, not featured evidence
22.1%B: Letrozole Then Letrozole + Palb
NCT02296801 · Phase 2 · registry result, not featured evidence · combination
27.5%C: Palbociclib Then Letrozole + Pa
NCT02296801 · Phase 2 · registry result, not featured evidence · combination
13.4%D: Letrozole + Palbociclib
NCT02296801 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone125 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
—125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
—125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
—Ph2P1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
—Ph2P2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
100%Phase 1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
97.6%Phase 2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone300 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone150 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone75 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone75 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone50 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone25 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone25 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestoneRibociclib + Fulvestrantm
NCT02422615 · Phase 3 · combination
show 34 more results
—Ribociclib + Fulvestrant (On-treat
NCT02422615 · Phase 3 · combination
59.9%
NCT02941926 · Phase 3 · combination
n/a: no completion milestoneRibociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Ribociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Crossover to Ribociclib + Letrozol
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
n/a: no completion milestoneRibociclib + Letrozole
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
68.7%Ribociclib + Letrozole Cohort A
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
—Ribociclib + Letrozole Cohort B
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
76.9%Ribociclib + Letrozole Cohort B1
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
87.9%Ribociclib + Letrozole Cohort B2
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestonePK Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—PK Cohort - Ribociclib (On-treatme
NCT03671330 · Phase 2 · registry result, not featured evidence
—PK Cohort - Ribociclib (Post-treat
NCT03671330 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonePostmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonePremenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone600 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—600mg
NCT03822468 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—400mg
NCT03822468 · Phase 2 · registry result, not featured evidence
0%
NCT03477396 · Phase 2 · registry result, not featured evidence · combination
68.8%600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
3.2%
NCT02632045 · Phase 2 · registry result, not featured evidence · combination
50%
NCT03078751 · Phase 2 · registry result, not featured evidence · combination
—600 mg
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
—500 mg
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
—400 mg
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
—300 mg
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
7.7%Cohort B: Ribociclib + Trastuzumab
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort C: Ribociclib + Trastuzumab
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
Discontinued due to AEs
7.2%l
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 48 more results
8.9%
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
3.9%Palbociclib+Letrozole Australia Co
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
2%Palbociclib+Letrozole India Cohort
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
5.2%Cohort 1: Palbociclib Plus Exemest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
2%Cohort 2: Palbociclib Plus Fulvest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
5.2%
NCT01864746 · Phase 3 · registry result, not featured evidence
2.3%
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
—
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
—
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
—
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
—125mg
NCT02630693 · Phase 2 · registry result, not featured evidence
—100mg
NCT02630693 · Phase 2 · registry result, not featured evidence
—
NCT02668666 · Phase 2 · registry result, not featured evidence
—
NCT03644186 · Phase 2 · registry result, not featured evidence · combination
—
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
—
NCT02536742 · Phase 2 · registry result, not featured evidence
—Single Agent T-DM1
NCT03530696 · Phase 2 · registry result, not featured evidence
—T-DM1 With Palbociclib
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
—
NCT03691493 · Phase 2 · registry result, not featured evidence · combination
0.9%
NCT04436744 · Phase 2 · registry result, not featured evidence · combination
—125mg
NCT02384239 · Phase 2 · registry result, not featured evidence
—100mg
NCT02384239 · Phase 2 · registry result, not featured evidence
—B: Letrozole Then Letrozole + Palb
NCT02296801 · Phase 2 · registry result, not featured evidence · combination
—C: Palbociclib Then Letrozole + Pa
NCT02296801 · Phase 2 · registry result, not featured evidence · combination
—D: Letrozole + Palbociclib
NCT02296801 · Phase 2 · registry result, not featured evidence · combination
0%125 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
—125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
—125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
16.7%100 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
—Ph2P1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
—Ph2P2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
0%Phase 1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
15.5%Phase 2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
—300 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—150 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—75 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—75 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—50 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—25 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—25 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
10.5%Ribociclib + Fulvestrantm
NCT02422615 · Phase 3 · combination
show 34 more results
—Ribociclib + Fulvestrant (On-treat
NCT02422615 · Phase 3 · combination
15.5%
NCT02941926 · Phase 3 · combination
4.8%Ribociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Ribociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Crossover to Ribociclib + Letrozol
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
11.4%Ribociclib + Letrozole
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
22.6%Ribociclib + Letrozole Cohort A
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
—Ribociclib + Letrozole Cohort B
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
23.1%Ribociclib + Letrozole Cohort B1
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
17.8%Ribociclib + Letrozole Cohort B2
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
11.8%PK Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—PK Cohort - Ribociclib (On-treatme
NCT03671330 · Phase 2 · registry result, not featured evidence
—PK Cohort - Ribociclib (Post-treat
NCT03671330 · Phase 2 · registry result, not featured evidence
6.5%Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
1.3%Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
12.8%600 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—600mg
NCT03822468 · Phase 2 · registry result, not featured evidence
11.2%400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—400mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—
NCT03477396 · Phase 2 · registry result, not featured evidence · combination
7.1%600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
—
NCT02632045 · Phase 2 · registry result, not featured evidence · combination
15.4%
NCT03078751 · Phase 2 · registry result, not featured evidence · combination
—600 mg
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
—500 mg
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
—400 mg
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
—300 mg
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort B: Ribociclib + Trastuzumab
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort C: Ribociclib + Trastuzumab
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
Serious AEs
28.2%l
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 48 more results
22.6%
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
20.2%
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
29.6%Palbociclib+Letrozole Australia Co
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
18%Palbociclib+Letrozole India Cohort
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
22.7%Cohort 1: Palbociclib Plus Exemest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
14.1%Cohort 2: Palbociclib Plus Fulvest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
10.1%
NCT01864746 · Phase 3 · registry result, not featured evidence
24.6%
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
—
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
38%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
15.7%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
13.5%125mg
NCT02630693 · Phase 2 · registry result, not featured evidence
10%100mg
NCT02630693 · Phase 2 · registry result, not featured evidence
32.7%
NCT02668666 · Phase 2 · registry result, not featured evidence
54.2%
NCT03644186 · Phase 2 · registry result, not featured evidence · combination
27.8%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
73%
NCT02536742 · Phase 2 · registry result, not featured evidence
21.4%Single Agent T-DM1
NCT03530696 · Phase 2 · registry result, not featured evidence
21.1%T-DM1 With Palbociclib
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
—
NCT03691493 · Phase 2 · registry result, not featured evidence · combination
4.5%
NCT04436744 · Phase 2 · registry result, not featured evidence · combination
5.9%125mg
NCT02384239 · Phase 2 · registry result, not featured evidence
13.9%100mg
NCT02384239 · Phase 2 · registry result, not featured evidence
—B: Letrozole Then Letrozole + Palb
NCT02296801 · Phase 2 · registry result, not featured evidence · combination
—C: Palbociclib Then Letrozole + Pa
NCT02296801 · Phase 2 · registry result, not featured evidence · combination
—D: Letrozole + Palbociclib
NCT02296801 · Phase 2 · registry result, not featured evidence · combination
0%125 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
9.5%125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
33.3%125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
0%100 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
30.3%Ph2P1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
24%Ph2P2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
16.7%Phase 1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
26.5%Phase 2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
20%300 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
33.3%150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
0%150 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
13.3%150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
16.7%100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
33.3%100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
16.7%75 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
0%75 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
0%50 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
11.1%50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
0%50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
12%50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
20%25 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
40%25 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—Ribociclib + Fulvestrantm
NCT02422615 · Phase 3 · combination
show 34 more results
37.1%Ribociclib + Fulvestrant (On-treat
NCT02422615 · Phase 3 · combination
—
NCT02941926 · Phase 3 · combination
—Ribociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
24.2%Ribociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
25%Crossover to Ribociclib + Letrozol
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
32.3%Ribociclib + Letrozole
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
30.4%Ribociclib + Letrozole Cohort A
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
27.3%Ribociclib + Letrozole Cohort B
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
19.2%Ribociclib + Letrozole Cohort B1
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
28.7%Ribociclib + Letrozole Cohort B2
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
—PK Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
29.4%PK Cohort - Ribociclib (On-treatme
NCT03671330 · Phase 2 · registry result, not featured evidence
0%PK Cohort - Ribociclib (Post-treat
NCT03671330 · Phase 2 · registry result, not featured evidence
—Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
27.3%Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
0%Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
17.7%Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
0%Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
19.7%600mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
20.2%400mg
NCT03822468 · Phase 2 · registry result, not featured evidence
0%
NCT03477396 · Phase 2 · registry result, not featured evidence · combination
—600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
15.2%600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
6.7%
NCT02632045 · Phase 2 · registry result, not featured evidence · combination
15.4%
NCT03078751 · Phase 2 · registry result, not featured evidence · combination
100%600 mg
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
100%500 mg
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
100%400 mg
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
100%300 mg
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
83.3%Cohort B: Ribociclib + Trastuzumab
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort C: Ribociclib + Trastuzumab
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
Most frequent reported AEs
l
neutropenia 69.4% (placebo 3.6%)
arthralgia 42.1% (placebo 40.1%)
fatigue 41.2% (placebo 29.3%)
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 42 more results
neutropenia 67%
fatigue 43.8%
nausea 36.5%
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
neutrophil count decreased 66.7% (placebo 11.1%)
white blood cell count decreased 64.3% (placebo 9.9%)
neutropenia 44.6% (placebo 7%)
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
neutropenia 72.4%
fatigue 65.1%
nausea 37.5%
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
neutropenia 57%
anaemia 22%
alopecia 17%
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
neutrophil count decreased 62.7%
fatigue 55.3%
hypertension 34%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 63.1%
fatigue 51%
hypertension 36.9%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
leukopenia 99.2% (placebo 69.9%)
neutropenia 95.7% (placebo 23.4%)
anemia 73.9% (placebo 30.3%)
NCT01864746 · Phase 3 · registry result, not featured evidence
neutropenia 70%
leukopenia 34.6%
anaemia 33.8%
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 92.4%
white blood cell decreased 87%
fatigue 84.8%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 92.2%
nausea 52.9%
stomatitis 41.2%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
125mg
fatigue 82%
nausea 53.9%
back pain 46.1%
NCT02630693 · Phase 2 · registry result, not featured evidence
100mg
fatigue 85.6%
nausea 52.2%
insomnia 48.9%
NCT02630693 · Phase 2 · registry result, not featured evidence
neutrophil count decreased 71.4%
fatigue 65.3%
white blood cell decreased 65.3%
NCT02668666 · Phase 2 · registry result, not featured evidence
diarrhea 65.3%
anemia 48.6%
platelet count decreased 38.9%
NCT03644186 · Phase 2 · registry result, not featured evidence · combination
white blood cell count decreased 96.3%
neutrophil count decreased 87%
anemia 79.6%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
nausea 57.1%
aspartate aminotransferase increased 50%
fatigue 50%
NCT03530696 · Phase 2 · registry result, not featured evidence
neutrophil count decreased 84.2%
platelet count decreased 76.3%
white blood cell count decreased 76.3%
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
neutropenia 41.1%
neutrophil count decreased 23.2%
asthenia 22.3%
NCT04436744 · Phase 2 · registry result, not featured evidence · combination
125mg
neutrophil count decreased 26.5%
hypertension 0%
NCT02384239 · Phase 2 · registry result, not featured evidence
100mg
neutrophil count decreased 13.9%
hypertension 5.6%
NCT02384239 · Phase 2 · registry result, not featured evidence
125 mg
white blood cell count decreased 83.3%
diarrhoea 66.7%
neutrophil count decreased 66.7%
NCT01684215 · Phase 2 · registry result, not featured evidence
125 mg + 2.5 mg
neutrophil count decreased 81%
stomatitis 76.2%
white blood cell count decreased 71.4%
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
125 mg + 2.5 mg
neutrophil count decreased 100%
white blood cell count decreased 100%
diarrhoea 66.7%
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
100 mg
neutrophil count decreased 83.3%
white blood cell count decreased 66.7%
aspartate aminotransferase increased 33.3%
NCT01684215 · Phase 2 · registry result, not featured evidence
neutropenia 78.8%
leukopenia 48.5%
fatigue 42.4%
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
neutropenia 72%
fatigue 40%
leukopenia 40%
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
neutropenia 91.7%
fatigue 83.3%
leukopenia 66.7%
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
neutropenia 74.7%
leukopenia 43.4%
fatigue 41%
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
300 mg QD
nausea 40%
fatigue 30%
headache 30%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
150 mg QD
neutrophil count decreased 100%
anaemia 66.7%
fatigue 66.7%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
150 mg BID
abdominal pain 66.7%
ggt increased 66.7%
nausea 66.7%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
150 mg QD
nausea 40%
headache 26.7%
hypertension 26.7%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
100 mg QD
white blood cell count decreased 91.7%
neutrophil count decreased 58.3%
anaemia 41.7%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
100 mg QD
abdominal pain upper 33.3%
arthralgia 33.3%
back pain 33.3%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
75 mg BID
arthralgia 33.3%
fall 33.3%
fatigue 33.3%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
75 mg QD
hypophosphataemia 66.7%
blood alkaline phosphatase increased 33.3%
breast pain 33.3%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
50 mg BID
alt increased 50%
anaemia 50%
cough 50%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
50 mg QD
neutrophil count decreased 77.8%
white blood cell count decreased 77.8%
anaemia 66.7%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
50 mg QD
fatigue 25%
ggt increased 18.8%
arthralgia 12.5%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
50 mg QD
ggt increased 14.7%
covid-19 10.7%
ast increased 9.3%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
25 mg BID
nausea 60%
neutrophil count decreased 60%
white blood cell count decreased 60%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
25 mg QD
neutrophil count decreased 80%
white blood cell count decreased 70%
anaemia 50%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
m
neutropenia 57.8% (placebo 2.5%)
nausea 46.8% (placebo 31.1%)
diarrhoea 34% (placebo 22.4%)
NCT02422615 · Phase 3 · combination
show 24 more results
neutropenia 57.9% (placebo 6.5%)
arthralgia 38.8% (placebo 36.2%)
neutrophil count decreased 35.5% (placebo 1.5%)
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
nausea 75% (placebo 32.1%)
anaemia 50% (placebo 7.3%)
diarrhoea 50% (placebo 26.7%)
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
neutropenia 65.3% (placebo 5.5%)
nausea 54.8% (placebo 32.1%)
fatigue 43.4% (placebo 36.1%)
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
neutropenia 50.8%
nausea 40.8%
fatigue 38.6%
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
neutropenia 48.1%
nausea 42.1%
fatigue 40.4%
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
fatigue 57.7%
neutropenia 57.7%
hot flush 42.3%
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
neutropenia 46.5%
nausea 43.3%
fatigue 37.6%
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 100% (placebo 23.4%)
white blood cell count decreased 100% (placebo 33.8%)
anaemia 94.1% (placebo 13%)
NCT03671330 · Phase 2 · registry result, not featured evidence
aspartate aminotransferase increased 12.5% (placebo 40.3%)
blood alkaline phosphatase increased 6.3% (placebo 27.3%)
blood cholesterol increased 6.3% (placebo 16.9%)
NCT03671330 · Phase 2 · registry result, not featured evidence
neutrophil count decreased 85.7% (placebo 23.4%)
white blood cell count decreased 80.5% (placebo 33.8%)
anaemia 48.1% (placebo 13%)
NCT03671330 · Phase 2 · registry result, not featured evidence
alanine aminotransferase increased 1.4% (placebo 40.3%)
aspartate aminotransferase increased 1.4% (placebo 40.3%)
blood bilirubin increased 1.4% (placebo 13%)
NCT03671330 · Phase 2 · registry result, not featured evidence
neutrophil count decreased 88.6% (placebo 23.4%)
white blood cell count decreased 87.3% (placebo 33.8%)
anaemia 55.7% (placebo 13%)
NCT03671330 · Phase 2 · registry result, not featured evidence
neutrophil count decreased 2.7% (placebo 23.4%)
alanine aminotransferase increased 1.4% (placebo 40.3%)
aspartate aminotransferase increased 1.4% (placebo 40.3%)
NCT03671330 · Phase 2 · registry result, not featured evidence
600mg
neutropenia 66.5%
leukopenia 27.7%
anaemia 26.1%
NCT03822468 · Phase 2 · registry result, not featured evidence
400mg
neutropenia 53.2%
alanine aminotransferase increased 26.1%
aspartate aminotransferase increased 21.8%
NCT03822468 · Phase 2 · registry result, not featured evidence
alanine aminotransferase increased 100%
alkaline phosphatase increased 100%
aspartate aminotransferase increased 100%
NCT03477396 · Phase 2 · registry result, not featured evidence · combination
600 mg
neutropenia 65.2%
anaemia 35.7%
leukopenia 25.9%
NCT03839823 · Phase 2 · registry result, not featured evidence
neutropenia 71.7% (placebo 15.3%)
fatigue 33.3% (placebo 32.2%)
aspartate aminotransferase increased 25% (placebo 28.8%)
NCT02632045 · Phase 2 · registry result, not featured evidence · combination
neutropenia 53.8% (placebo 0%)
fatigue 46.2% (placebo 4.2%)
nausea 46.2% (placebo 25%)
NCT03078751 · Phase 2 · registry result, not featured evidence · combination
600 mg
neutrophil count decreased 100%
platelet count decreased 100%
anemia 66.7%
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
500 mg
neutrophil count decreased 100%
platelet count decreased 100%
anemia 66.7%
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
400 mg
anemia 100%
platelet count decreased 100%
white blood cell decreased 100%
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
300 mg
anemia 100%
platelet count decreased 100%
white blood cell decreased 100%
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
anemia 83.3%
diarrhea 41.7%
nausea 41.7%
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination

Notes

  1. aPopulation context differs: eligible sex differs (ALL versus FEMALE).
  2. bThe assessment timepoint is not available for both results.
  3. cTrial phases differ: Phase 2 versus Phase 3.
  4. dPopulation comparability has not been reviewed for both studies.
  5. eTrial phases differ: Phase 3 versus Phase 2.
  6. fTreatment context has not been resolved for both arms.
  7. gThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  8. hPopulation context differs: registered conditions differ.
  9. iTrial phases differ: Phase 3 versus Phase 1/2.
  10. jTreatment context differs: combination versus monotherapy.
  11. kTrial phases differ: Phase 1/2 versus Phase 2.
  12. lPopulation comparability has not been reviewed for 46 of these studies.
  13. mPopulation comparability has not been reviewed for 31 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Palbociclib

Complete 1% (n=100)
responder rate · % of participants
No placebo or comparator arm
Percentage of participants with complete response
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
1.3% (n=152)
Percentage of participants with complete response
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
Partial 28% (n=100)
responder rate · % of participants
No placebo or comparator arm
Percentage of participants with partial response
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
11.8% (n=152)
Percentage of participants with partial response
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
ORR 29% (n=100)
absolute value · percentage points
No placebo or comparator arm
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
show 3 more results
13.2% (n=152)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
24.8% (n=129)
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
55% (n=47)
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
EQ-5D Utility 0.698 score
absolute value · score
No placebo or comparator arm
End of Treatment (EOT)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
EQ-5D Utility -0.147 score
absolute change · score
No placebo or comparator arm
End of Treatment (EOT)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
EQ-5D-VAS 73.6 score
absolute value · score
No placebo or comparator arm
End of Treatment (EOT)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
EQ-5D VAS -3.2 score
absolute change · score
No placebo or comparator arm
End of Treatment (EOT)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
EORTC QLQ-C30 Global Health Status 3.28 vs 1.97 Capecitabine score
absolute change · score
Global health status / QoL
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Physical Functioning -1.73 vs -2.94 Capecitabine score
absolute change · score
Physical functioning
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Role Functioning -1.09 vs -4.97 Capecitabine score
absolute change · score
Role functioning
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Emotional Functioning 6.78 vs 8.67 Capecitabine score
absolute change · score
Emotional functioning
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Cognitive Functioning -2.18 vs -2.42 Capecitabine score
absolute change · score
Cognitive functioning
NCT02028507 · Phase 3 · registry result, not featured evidence · combination

+ 65 further endpoints in the CSV export.

Ribociclib

Time to Response 4.9 vs 3.2 Combination Chemotherapy months600 mg
time to event · months
NCT03839823 · Phase 2 · registry result, not featured evidence
show 4 more results
NA vs NA placebo months
NCT02422615 · Phase 3 · combination
NA vs NA placebo months
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
3.7 vs 5.5 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
3.6 vs 5.5 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
Time to Progression 27.1 months
time to event · months
No placebo or comparator arm
NCT02941926 · Phase 3 · combination
FACT-B 0.2 score @ 4wk
absolute change · score
No placebo or comparator arm
Cycle 2 Day 1
NCT02941926 · Phase 3 · combination
FACT-B 0.1 score @ 8wk
absolute change · score
No placebo or comparator arm
Cycle 3 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -0.3 score @ 12wk
absolute change · score
No placebo or comparator arm
Cycle 4 Day 1
NCT02941926 · Phase 3 · combination
FACT-B 0 score @ 16wk
absolute change · score
No placebo or comparator arm
Cycle 5 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -0.8 score @ 20wk
absolute change · score
No placebo or comparator arm
Cycle 6 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -0.9 score @ 28wk
absolute change · score
No placebo or comparator arm
Cycle 8 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -1.2 score @ 36wk
absolute change · score
No placebo or comparator arm
Cycle 10 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -1.6 score @ 44wk
absolute change · score
No placebo or comparator arm
Cycle 12 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -2 score @ 56wk
absolute change · score
No placebo or comparator arm
Cycle 15 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -2 score @ 68wk
absolute change · score
No placebo or comparator arm
Cycle 18 Day 1
NCT02941926 · Phase 3 · combination

+ 36 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Palbociclib's landscape · Ribociclib's landscape